BMY
Bristol-Myers Squibb Company $BMY clears the buy point$BMR is breaking out the buy point of cup w handle.
If you find my charts useful, please just leave me "like"
thank you
Market Review - Monday, 27 January 2020MCD, GOLD, BMY, ETR, AZN, BHP, BMY, CAG, CI, CL, DTE, GWW, HUM, K, L, NKE, RIO, Y, TJX
Nektar is reaching fair valueNektar and Bristol-Myers Squibb announced today the companies have agreed to a new joint development plan to advance bempegaldesleukin (bempeg) plus Opdivo (nivolumab) into multiple new registrational trials (source: Yahoo Finance).
The 19% jump is making Nektar trading around its fair value. Likely, profit-taking will take place in the next sessions. I'm expecting the stock price to consolidate around $23 level.
Disclosure: My ideas contain statements and projections based on assumptions on capital markets, and therefore inherently subject to numerous risks and uncertainties.
Before buying or selling any stock you should do your own research and reach your own conclusion or consult a financial advisor. Investing includes risks, including loss of principal.
I am not a financial advisor.
Don't forget to support this idea, if you liked it, and to follow me here on TradingView.
Investing Fellow
Market Review - Monday, 13 January 2020ETR, BMY, MCD, GOLD, AZN, CAG, CPB, KR, L, LMT, NEM, NOC, Y, RTN
BMY oh boy , feels like this one is about show some money on 26 it is a sleeper , but profit margin of 24% is one of the best in its own class , very bullish here .. on chart at list :D
posting my opinion only, never trade money you need to buy food and pay bills ..
Happy trading !
MERCK IS DIRT CHEAP. $11 BILLION CANCER DRUG. SALES BOOMING!We keep seeing Clinical Stage Companies that are publicly traded, with new FDA Approvals, and the stocks are blasting off. Many of those are trading over $100 with no revenue, profits or earnings.
Here Merck is, sitting under $100, beating earnings, with record revenue and profit, and paying an almost 3.00% dividend....It is simply outrageous. Wall Street Corruption at it's best!
We took a long position at $82.00 several weeks ago.
We feel the stock is worth at minimum, $150.00 all day long.
KEYTRUDA alone, not counting any other products manufactured / developed by Merck, or any other divisions of Merck, is forecast to bring in over $11 Billion in sales.
Holding for the almost 3% Dividend and for the stock price appreciation into the future.
250,000 LONG @ $82.00
Best of Luck Everyone!
i30.Bristol-Myers Squibb Beta-R:Journal. Risk Management: Compound .Level : PA . Time: Short-term - Intermediate . This is just my view follow if it aligns with yours. Ideas are not repeated rather updated.Worry about risk only.
BMY Huge OI for September Calls @ $50 and $48Bristol Myers Sept.Calls bought by the thousands. So, why not?
BYND Strong IPOBYND is in a strong and tight bull channel since the IPO. This bull trend from the open is what a trader wants to see when buying for long term investments. Last week formed a reversal attempt. When the market is strong, first reversal attempts fail 80% of the time and instead create the start of a second leg up. The bears will likely need some form of second reversal attempt like a large low 2 or failed bull breakout (they act the same), in order to increase the likelihood of reversing the bull spike. Even if there is a good bear reversal, the bulls will likely look to buy again around the 50 open. If the bear pressure is not strong, the bulls will look to form a spike and bull channel which usually forms after two legs sideways to down, and generally stem from a high 2 or wedge bull flag.
If you found this helpful please like and share! Feel free to comment or ask questions.
BMY Is starting a bull moveHey everyone,
Another biomed related post today by request.
BMY has double-bottomed as bulls grab a little control today on price.
The stock has respected the BBands and is looking to move to the neutral region.
The RSI teased in the oversold area, and price has responded with one of the two strong bull movements in the past four weeks as far as price movement goes.
Price will struggle to break the $48.31 resistance that the massive bull volume failed to break on the 29th.
We want to look for increasing bull volume as price recovers after hitting a low.
If bull volume recovers with the next successive days, look at the $48.31 target for the first movement, with the $54 mark if price breaks through for the second movement.
If bear volume trends or increasing in the next few days below the 45.15 support, the stock could break lower forming new lows for the year.
Keep a tight stop loss in the meantime at the lower $45.15 support and long for the 48.31 and eventually the 54.44 if price starts to trend up with volume or if it ventures beyond the restraints of the BBands.
-Block
BMY is approaching support, potential bounce! BMY is approaching our first support at 47.85 where we might see a bounce in price to our resistance at 51.12. Stochastic is also approaching support where we might see a corresponding bounce in price.
BMY approaching support, potential bounce! BMY is approaching our first support where we might see a bounce in price to our first resistance level.
Stochastic is also approaching support.
BMY appraoching resistance, potential drop! BMY is approaching our first resistance at 54.09 (horizontal swing high resistance, 50% Fibonacci retracement, 100% fibonacci extension) where a strong drop might occur below this level pushing price down to our major support at 50.25 (61.8% fibonacci retraecement, horizontal swing low support).
Stochastic (34,5,3) is also approaching resistance where we might see a corresponding drop in price.
BMY approaching resistance, potential drop!BMY is approaching our first resistance at 52.42(horizontal siwng high resistance, 61.8%, 100% fibonacci extension, 76.4%, 38.2% fibonacci retracement) where a strong drop might occur pushing price down to our major support at 48.35 (horizontal overlap support, 50% fibonacci retracement).
Stochastic (89,5,3) is also approaching resistance where we might see a corresponding drop in price.
